Accelrys Non-compliant with Nasdaq Listing Rule | GenomeWeb

NEW YORK (GenomeWeb News) – Accelrys said on Friday that it has been notified by Nasdaq that the company does not comply with a listing requirement that its audit committee be comprised of three independent directors.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: variant linked to obesity risk in Samoans, health of cloned animals, and more.

Researchers explore using genome editing to treat inherited eye diseases, New Scientist reports.

Olympic athletes this summer will also undergo gene doping testing, according to Wired.

A study finds that the lower funding rate seen among women of color is more due to race than gender, according to BuzzFeed News.